Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00502710 · ClinicalTrials.gov registry record · Phase 2
A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
NCT00502710 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 289 participants.
The verdict
NCT00502710, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
Study Summary
This 5 arm study will assess the efficacy, pharmacokinetics, safety and tolerability of a DPP-IV inhibitor compared to placebo in patients with type 2 diabetes. Patients will be randomized to receive DPP-IV(3) at one of 4 doses (of 12.5mg and above), or placebo p.o. Patients receiving metformin before the study will continue on the same dose of metformin. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Interventions
- DRUG Placebo
- DRUG RO4876904
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00502710
The ClinicalTrials.gov registry entry for NCT00502710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 289 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00502710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00502710 about?
NCT00502710 is a clinical study titled "A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.". This 5 arm study will assess the efficacy, pharmacokinetics, safety and tolerability of a DPP-IV inhibitor compared to placebo in patients with type 2 diabetes. Patients will be randomized to receive DPP-IV(3) at one of 4 doses (of 12.5mg and above), or placebo p.o. Patients receiving metformin befo...
What is the current status of trial NCT00502710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2007-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00502710?
The interventions under investigation include: Placebo (DRUG), RO4876904 (DRUG).
Who is sponsoring clinical trial NCT00502710?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.